Table 2.
Radiological assessments and baseline SLD of target lesions
| Patients with adenocarcinoma histology NSCLC | Patients with squamous cell histology NSCLC | |||||||
|---|---|---|---|---|---|---|---|---|
| All | TSFLT <9 | PD-FLT | ||||||
| Nintedanib (n=322) | Placebo (n=336) | Nintedanib (n=206) | Placebo (n=199) | Nintedanib (n=53) | Placebo (n=64) | Nintedanib (n=276) | Placebo (n=279) | |
| Patients with at least one valid post-baseline image,a n (%) | 306 (95.0) | 308 (91.7) | 196 (95.1) | 178 (89.4) | 49 (92.5) | 56 (87.5) | 252 (91.3) | 250 (89.6) |
| Number of valid post-baseline images | 1,273 | 1,125 | 769 | 513 | 230 | 149 | 843 | 737 |
| Number of valid post-baseline images per patient, median (range) | 3 (1–28) | 3 (1–21) | 3 (1–21) | 2 (1–20) | 3 (1–21) | 2 (1–13) | 2 (1–24) | 2 (1–24) |
| Estimated mean (range) baseline SLDb measurements (mm) | 82.5 (10.9–391.2) | 88.3 (11.2–391.2) | 98.1 (11.5–391.2) | 94.3 (11.3–313.9) | ||||
Notes:
a
Either CT or MRI scan, with the same method used consistently for an individual patient.
b
Estimated fixed effects of longitudinal mixed model; the intercept of SLD was at Month 0.
Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; NSCLC, non-small-cell lung cancer; PD-FLT, progressive disease as the best response to first-line therapy; SLD, sum of longest diameter; TSFLT <9, time from start of first-line therapy <9 months.